KURA (Kura Oncology) Other Long-Term Liabilities: $3.62 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KURA Kura Oncology Inc KURA
28 GF Score
Price $12.35
! 8 Warning Signs
View Full Analysis

What is Kura Oncology Other Long-Term Liabilities?

Kura Oncology KURA +9.31% 28 Other Long-Term Liabilities is $3.62 Mil as of Jun. 2026. GuruFocus rates KURA with a GF Score™ of 28/100. The stock has 8 warning signs investors should review.

Kura Oncology's other long-term liabilities for the quarter that ended in Jun. 2026 was $3.62 Mil.

Kura Oncology's quarterly other long-term liabilities increased from Dec. 2025 ($3.16 Mil) to Mar. 2026 ($3.44 Mil) and increased from Mar. 2026 ($3.44 Mil) to Jun. 2026 ($3.62 Mil).

Kura Oncology's annual other long-term liabilities increased from Dec. 2023 ($0.71 Mil) to Dec. 2024 ($1.80 Mil) and increased from Dec. 2024 ($1.80 Mil) to Dec. 2025 ($3.16 Mil).

Kura Oncology Other Long-Term Liabilities Related Terms

Kura Oncology Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Kura Oncology's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kura Oncology Other Long-Term Liabilities Chart

Kura Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.27 0.71 1.80 3.16

Kura Oncology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.60 2.98 3.16 3.44 3.62
KURA
28GF Score
Kura Oncology Inc KURA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kura Oncology Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $3.62 Mil mean?
Kura Oncology (KURA) has a Other Long-Term Liabilities of $3.62 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kura Oncology and its competitors.
Is Kura Oncology's Other Long-Term Liabilities too high?
Kura Oncology's current Other Long-Term Liabilities is $3.62 Mil. Overall, Kura Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's Other Long-Term Liabilities compare to PHAT and GERN?
Kura Oncology's Other Long-Term Liabilities of $3.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kura Oncology and its competitors. Kura Oncology's current Other Long-Term Liabilities is $3.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (KURA) has a current Other Long-Term Liabilities of $3.62 Mil. The current Other Long-Term Liabilities is $3.62 Mil. Kura Oncology's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Kura Oncology (KURA), the current Other Long-Term Liabilities is $3.62 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kura Oncology Business Description

Other Exchanges KUR:Germany
Address 4930 Directors Place, Suite 500, San Diego, CA, USA, 92121
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
28GF Score

Get the complete analysis for KURA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.35
Price